1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Caribou’s Phase I CAR-T Data In Lymphoma Show Improvement In Durability

 
• By Alaric DeArment

CB-010 still has a way to go, but data from 16 patients in the ANTLER trial showed a higher six-month CR rate than when the company reported data for five patients at EHA in 2022.

Caribou announced updated Phase I data from the ANTLER trial of allogeneic CAR-T CB-010 in non-Hodgkin lymphomas • Source: Shutterstock

Updated data from Caribou Biosciences, Inc.’s Phase I ANTLER trial of its off-the-shelf CD19-directed CAR-T cell therapy, CB-010, show better results than before in terms of durability of response among patients with large B-cell lymphoma (LBCL) and other B-cell non-Hodgkin lymphomas (NHL), although the numbers remain small. The company is moving ahead to determine a recommended Phase II dose.

Caribou announced the updated data on 13 July for all 16 patients treated in the dose-escalation portion of ANTLER, 10...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 
• By Alaric DeArment

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.